This paper examines how people in West Africa are reacting to the Ebola virus 
disease, an epidemic presently prevalent in the region. Certain lifestyle 
changes are suggested. Additionally, the heart of the paper focuses on the 
request by governments to be allowed access to experimental drugs, such as Zmapp 
and TKM-Ebola, for their infected populations. The author argues that granting 
such a request would circumvent research ethics procedures, which could 
potentially constitute significant risk to users of the drugs. The Pfizer Kano 
meningitis trial of 1996 is cited as an example to buttress how unapproved drugs 
could prove fatal.